{
    "clinical_study": {
        "@rank": "53598", 
        "arm_group": [
            {
                "arm_group_label": "GSK1605786 500 mg once daily", 
                "arm_group_type": "Experimental", 
                "description": "GSK1605786 500 mg is given once daily in the morning"
            }, 
            {
                "arm_group_label": "GSK1605786 500 mg twice daily", 
                "arm_group_type": "Experimental", 
                "description": "GSK1605786 500 mg is given twice daily in the morning and in the evening"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open-label, parallel group, single and repeat dose pharmacokinetic (PK) study in\n      healthy male and female subjects. This study will confirm the PK and safety profile in\n      Chinese subjects. GSK1605786 is currently in clinical development for the treatment of\n      Crohn's disease. Subjects will receive one of two GSK1605786 doses (500 mg once daily or\n      500mg twice daily) within 30 minutes after a meal. The study will consist of single and\n      repeat dose sessions, with pre-dose and serial PK samples taken up to 72-h post-dose."
        }, 
        "brief_title": "Single and Repeat Dose Pharmacokinetic Study of GSK1605786 in Healthy Chinese Subjects", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Crohn's Disease", 
        "condition_browse": {
            "mesh_term": "Crohn Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy as determined by a responsible and experienced physician, based on a medical\n             evaluation including medical history, physical examination, laboratory tests and ECG\n\n          -  Male or female between 18 and 45 years of age\n\n          -  Body weight 50 kg (110lbs) for men and women, and body mass index (BMI) within the\n             range 19 24 kg/m2\n\n        Exclusion Criteria:\n\n          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody\n             result within 3 months of screening\n\n          -  Current or chronic history of liver disease, or known hepatic or biliary\n\n          -  A positive test for HIV antibody at screening\n\n          -  Known coeliac disease and positive serologic testing for anti-tTG antibodies\n\n          -  A positive pre-study drug/alcohol screen\n\n          -  Lactating females"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "21", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01827631", 
            "org_study_id": "116416"
        }, 
        "intervention": {
            "arm_group_label": [
                "GSK1605786 500 mg twice daily", 
                "GSK1605786 500 mg once daily"
            ], 
            "description": "Swedish Orange, size 0, hard gelatine capsules", 
            "intervention_name": "GSK1605786 capsule", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "healthy", 
            "GSK1605786", 
            "CCR9 receptor antagonist", 
            "Chinese subjects", 
            "pharmacokinetics"
        ], 
        "lastchanged_date": "July 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "zip": "200025"
                }, 
                "name": "GSK Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Single and Repeat Dose Pharmacokinetic Study of GSK1605786 in Healthy Chinese Subjects", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "maximum concentration after single dose and repeat dose", 
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "up to 72 hour post dose"
            }, 
            {
                "description": "area under the concentration time curve during steady state", 
                "measure": "AUC(0-\u03c4)", 
                "safety_issue": "No", 
                "time_frame": "up to 24 hour post last dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01827631"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "AEs occur during the study", 
                "measure": "adverse events (AEs)", 
                "safety_issue": "No", 
                "time_frame": "up to 21 days, from the first dose until the follow-up visit"
            }, 
            {
                "description": "blood pressure, pulse rate, respiratory rate and temperature", 
                "measure": "vital signs", 
                "safety_issue": "No", 
                "time_frame": "before each morning dose on Day 1 and 8-14, and on Day 17 prior to leaving the clinic"
            }, 
            {
                "description": "Hematology/Clinical Chemistry/Urinalysis test", 
                "measure": "lab assessment", 
                "safety_issue": "No", 
                "time_frame": "Day 17 prior to leaving the clinic"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}